Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 835 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intramuscular vaccine Clear all

Conditions: COVID-19
Interventions: mRNA-1283.251 Variant-containing Formulation; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 832 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Atlanta, Georgia • Baton Rouge, Louisiana • New Orleans, Louisiana + 2 more

Conditions: Influenza
Interventions: Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more

Conditions: Cancer
Interventions: Intracel KLH Vaccine, Biosyn KLH, Montanide ISA51, Tetanus toxoid; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine; Biological
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Epstein-Barr Virus Infection
Interventions: mRNA-1189, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 10 Years to 30 Years
Enrollment: 867 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 65
States / cities: Huntsville, Alabama • Anaheim, California • Colton, California + 56 more

Conditions: Herpes Simplex
Interventions: GSK208141, Havrix (investigational formulation), Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 5,960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 66
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 54 more

Conditions: Warts
Interventions: Human Papillomavirus 9-valent Vaccine, Recombinant, Normal Saline; Biological · Other
Lead sponsor: Western Institute for Veterans Research; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Malaria
Interventions: RTS,S/AS01E, RTS,S/AS01B, Sporozoite-infected mosquitoes challenge.; Biological · Procedure
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Influenza
Interventions: Licensed seasonal influenza vaccine; Biological
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Healthy Volunteers
Interventions: NasoShield, BioThrax, Placebo; Biological · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Melbourne, Florida • San Antonio, Texas

Conditions: Influenza
Interventions: Influenza A/H5N1 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 452 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Torrance, California • Baltimore, Maryland • Rochester, New York

Conditions: Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis
Interventions: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM); Biological
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ebola Virus Disease, Marburg Virus Disease
Interventions: cAd3-Marburg, cAd3-EBO-S; Biological
Lead sponsor: Albert B. Sabin Vaccine Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Malaria
Interventions: BNT165b1, Placebo; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative, Fluzone High-Dose, vaccine, 2016-2017 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 3 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Bardstown, Kentucky • Metairie, Louisiana

Conditions: Respiratory Syncytial Virus Infections
Interventions: MVA-BN-RSV, Placebo; Biological · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 55 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Redding, California • San Diego, California • The Villages, Florida + 9 more

Conditions: Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
Interventions: Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 3 Years to 17 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 9
States / cities: San Francisco, California • Kansas City, Missouri • Cincinnati, Ohio + 6 more

Conditions: Meningitis, Meningococcemia, Pertussis, Tetanus, Diphtheria
Interventions: T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 1,345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Boulder, Colorado + 17 more

Conditions: SARS CoV 2 Infection
Interventions: IMNN-101; Biological
Lead sponsor: Imunon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Influenza
Interventions: H5N1 pISV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: SARS-CoV-2 Infection, COVID-19
Interventions: BNT162b2, Placebo, BNT162b2 OMI, Combination BNT162b2 and BNT162b2 OMI, Combination (Bivalent) BNT162b2 and BNT162b2 OMI; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 12 Years and older
Enrollment: 16,372 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 139
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 99 more

Conditions: GBS Disease, Streptococcus Agalactiae
Interventions: GBS trivalent vaccine, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Aurora, Colorado • Baltimore, Maryland • Durham, North Carolina + 3 more

Conditions: Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
Interventions: Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3, Varicella Virus Vaccine Live, Measles, Mumps, and Rubella Virus Vaccine Live, Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein], Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate), Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine* [Recombinant] *as applicable; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 15 Months
Enrollment: 852 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 49
States / cities: Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more

Conditions: Pertussis, Whooping Cough
Interventions: BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device; Combination Product
Lead sponsor: ILiAD Biotechnologies; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Cleveland, Ohio • Tomball, Texas • West Jordan, Utah

Search by objective public record fields.

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

Vaccination With Tetanus and KLH to Assess Immune Responses.

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Immune Response Following Seasonal Influenza Vaccination

NasoShield Study of Safety and Immunogenicity

A/H5N1in Adult - Aventis

Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults